Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia (GEMS)
Sleep Initiation and Maintenance Disorders, Insomnia
About this trial
This is an interventional treatment trial for Sleep Initiation and Maintenance Disorders focused on measuring Primary Insomnia, Sleeplessness, Early Awakening, Chronic Insomnia
Eligibility Criteria
Inclusion Criteria: Out patients Each patient must have primary insomnia in accordance with DSM-IV-TR-Axis I (Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition-Text Revision) criteria Based on patient's information, the patient must complain of at least one hour of wakefulness after sleep onset for at least 3 nights per week over the preceding month Patient must report impact daytime functioning associated with sleep maintenance insomnia as measured by question 3 of Insomnia Severity Index at screening visit and randomization visit. Exclusion Criteria: Females who are lactating or pregnant Woman of childbearing potential with a positive serum beta human chorionic gonadotropin pregnancy test at screening and not using an acceptable form of contraception Patients presenting with acute or chronic pain resulting in insomnia Patients with history of epilepsy or seizures Consumption of xanthine containing beverage (i.e. tea, coffee, or cola) comprising more than 5 glasses/day Evidence of any clinically significant, severe, or unstable acute or chronically progressive medical or surgical disorder which may affect patient safety BMI >32 Acute or chronic pain resulting in insomnia Patients with current psychiatric disorders according to DSM-IV-TR criteria, mental retardation, or dementia Clinically significant and abnormal EKG (QTc interval >=500 msec) Positive for hepatitis B or C Serious head injury or stroke within 1 year Use of OTC (over-the-counter) medications such as valerian root, kava, melatonin, St. John's Wort, or alluna; prescription sleep medications or anxiolytics within 1 week or 5 half-lives Participation in another trial within two month before the screening visit Use of any substance with psychotropic effects or properties known to affect sleep/wake Unable to complete the study questionnaires Night shift workers, and individuals who nap 3 or more times per week over the preceding month History of: Primary hypersomnia Narcolepsy Breathing-related sleep disorder (such as sleep apnea) Circadian rhythm sleep disorder Parasomnia (somnambulism) Dyssomnia (such as periodic leg movements)
Sites / Locations
- Sanofi-Aventis Administrative Office
- Sanofi-Aventis Administrative Office
- Sanofi-Aventis Administrative Office
- Sanofi-Aventis Administrative Office
- Sanofi-Aventis Administrative Office
- Sanofi-Aventis Administrative Office
- Sanofi-Aventis Administrative Office
- Sanofi-Aventis Administrative Office
- Sanofi-Aventis Administrative Office
- Sanofi-Aventis Administrative Office
- Sanofi-Aventis Administrative Office
- Sanofi-Aventis Administrative Office
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Eplivanserin
Placebo
Eplivanserin 5 mg/day
Placebo of Eplivanserin 5 mg /day